Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AWAKE real-world registry of solriamfetol for excessive daytime sleepiness in obstructive sleep apnea
ChiCTR2600132209Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of solriamfetol in obstructive sleep apnea hypopnea syndrome (OSAHS), sponsored by Peking Union Medical College Hospital. Primary endpoints: Functional Outcomes of Sleep Questionnaire – 10 Item Version, Driving-related questionnaire and 4 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
solriamfetol
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on ChiCTR2600132209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132209.